News

DIA, Chicago 2017

Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

New CRO unit facility welcomes first overnight patients

Richmond Pharmacology has been busy settling in their first patients at the new London Bridge site.

Richmond Pharmacology Opens New London Bridge Site

This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis.

Accelerated Early Phase Drug Development in the UK and Europe

Hear the latest updates about how early phase studies can be accelerated globally by starting first in human trials in the UK then rapidly progress into Europe. This will give you access to a population of 500 million people.

Inotrem successfully completes its first phase I clinical trial with Motrem™, a TREM-1 pathway modulator for the treatment of septic shock

Paris, France, September 13, 2016